Trial · NCT07882030
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Functional Independence at 90 Days | 90 ± 7 days after randomization | The proportion of participants achieving functional independence at 90 days after randomization, defined as a modified Rankin Scale (mRS) score of 0 to 2. The mRS ranges from 0 to 6, with higher scores indicating greater disability. |
| Secondary | Excellent Functional Outcome at 90 Days | 90 ± 7 days after randomization | The proportion of participants achieving an excellent functional outcome at 90 days after randomization, defined as a modified Rankin Scale (mRS) score of 0 to 1. |
| Secondary | Distribution of Modified Rankin Scale Scores at 90 Days | 90 ± 7 days after randomization | The distribution of modified Rankin Scale (mRS) scores from 0 to 6 at 90 days after randomization. Higher scores indicate greater disability. |
| Secondary | Change in Barthel Index From Baseline to Day 90 | Baseline to 90 ± 7 days after randomization | The change in Barthel Index score from baseline to 90 days after randomization. |
| Secondary | Change in NIHSS Score From Baseline to Day 14 | Baseline to day 14 ± 3 after randomization | The change in National Institutes of Health Stroke Scale (NIHSS) score from baseline to day 14 after randomization. The NIHSS ranges from 0 to 42, with higher scores indicating greater neurological impairment. |
| Secondary | Neurological Improvement at Day 14 | Day 14 ± 3 after randomization | The proportion of participants with neurological improvement at day 14 after randomization, defined as a reduction in NIHSS score of at least 4 points from baseline. |
| Secondary | Change in NIHSS Score From Baseline to Day 7 | Baseline to day 7 after randomization | The change in National Institutes of Health Stroke Scale (NIHSS) score from baseline to day 7 after randomization.The total NIHSS score ranges from 0 to 42, where higher scores represent greater neurological impairment (worse outcome). A decrease in score indicates improvement. |
| Secondary | Symptomatic Intracranial Hemorrhage Within 7 Days | Within 7 days after randomization | The proportion of participants experiencing symptomatic intracranial hemorrhage within 7 days after randomization, defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria. |
| Other | Serious Adverse Events Within 90 Days | From randomization through day 90 ± 7 | The proportion of participants experiencing at least one serious adverse event from randomization through day 90. |
| Other | All-Cause Mortality Within 90 Days | Within 90 ± 7 days after randomization | The proportion of participants who die from any cause within 90 days after randomization. |
| Other | Change in Serum Alanine Aminotransferase From Baseline to Day 7 | Baseline to day 7 after randomization | The change in serum alanine aminotransferase (ALT) concentration from baseline to day 7 after randomization. |
| Other | Change in Serum Aspartate Aminotransferase From Baseline to Day 7 | Baseline to day 7 after randomization | The change in serum aspartate aminotransferase (AST) concentration from baseline to day 7 after randomization. |
| Other | Change in Creatinine Clearance From Baseline to Day 7 | Baseline to day 7 after randomization | The change in creatinine clearance from baseline to day 7 after randomization. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07882030/registered